Loading...
•
Dec 31, 2025
Fortrea Q4 2025 Earnings Report
Fortrea Q4 2025 Earnings Report
Key Takeaways
Fortrea delivered fourth-quarter results in line with full-year targets, showing resilience after a challenging first half of the year. While revenue declined year-over-year, the company achieved a strong book-to-bill ratio of 1.14x and focused on debt reduction and cost-saving initiatives to strengthen its balance sheet.
Fourth quarter revenue reached $660.5 million, meeting the company's stated full-year targets despite a year-over-year decline.
Achieved a robust Q4 book-to-bill ratio of 1.14x, indicating strong new business awards and a journey back to growth.
GAAP net loss narrowed significantly to $32.5 million compared to a $73.9 million loss in the prior year's quarter.
The company successfully exceeded its full-year cost savings targets and continued disciplined capital allocation for debt paydown.
Forward Guidance
For the full year 2026, Fortrea expects revenue to be between $2.55 billion and $2.65 billion with Adjusted EBITDA between $190 million and $220 million.
Positive Outlook
- Targeting Adjusted EBITDA growth with a range up to $220 million
- Strong backlog of $7.7 billion providing future revenue visibility
- Positive feedback from large pharma and biotech clients
- Embedded commitment to operational and financial excellence
- Strengthened balance sheet through continued debt paydown
Challenges Ahead
- Full-year 2026 revenue guidance range is lower than 2025 actual revenue
- Potential for continued macroeconomic volatility in the biotech industry
- Risks associated with international operations and currency fluctuations
- Dependence on third parties for critical business services
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...